Login to Your Account

Anything but 'TDM' in San Antonio

Phase II Breast Data Dazzling; ImmunoGen on Royalty Road

By Randy Osborne

Tuesday, December 15, 2009
An eye-opening overall response rate of 32.7 percent in Phase II trials with antibody-drug conjugate TDM-1 in last-resort breast cancer patients left investors in ImmunoGen Inc. with well-founded hope that partner Roche Holdings AG will file for approval in the first half of next year and get an accelerated nod from the FDA. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription